mothertobaby semaglutide pregnancy fact sheet 2024 mothertobaby semaglutide pregnancy fact sheet Impact of semaglutide exposure on fetal and neonatal outcomes in pregnant Safety of Weight Loss Drugs:

If gastrointestinal side effects persist despite conservative measures, healthcare providers may consider alternative GLP-1 receptor agonists with different pharmacokinetic profiles, adjust the treatment regimen, or explore complementary therapies for diabetes or weight management

A big win for Wegovy: Weight loss drug semaglutide first in history to gain FDA approval for reducing heart risks Semaglutide, a GLP-1 receptor agonist from Novo Nordisk, originally developed to treat diabetes, has been approved by the U.S

Wegovy has an explicit weight loss indication, which makes it easier to get covered by plans that include anti-obesity medications

The drug's primary actions on GLP-1 receptors do not appear to involve effects on the gastrointestinal mucosa that would predispose to bleeding